Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc. (SNSE) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
snse · stock forecast · 6 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Buy
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$50.00
Consensus
$50.00
+284.6% upside
Low
$50.00
Median: $50 · Last Close: $13.00
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $12.35 | ↓ 5.00% |
1-day model range: $11.9–$12.8. Peak: $12.8 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · SNSE · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-10-30 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-08-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-28 | Oppenheimer | Maintains | Outperform→Outperform |
| 2025-03-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-24 | Stephens & Co. | Maintains | Overweight→Overweight |
| 2024-05-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-12-13 | Citigroup | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Sensei Biotherapeutics, Inc. (SNSE) stock. Of the recent 16 rating actions, 1 were upgrades and 3 were downgrades. 6 analysts currently cover SNSE.
Analyst Recommendation Trends
SNSE analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$0M
EPS This Year
$-81.89
EPS Next Year
$-6.52
↓ 92.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast SNSE EPS of $-81.89 for the current fiscal year, based on estimates from 2 analysts. The SNSE revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The SNSE stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SNSE price target is $50.00 (+284.6% upside), with an analyst consensus of Buy.
The SNSE short-term stock prediction for tomorrow is $12.35 (-5.00%).
Sensei Biotherapeutics, Inc. trades on NASDAQ under the ticker SNSE. The SNSE stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
SNSE forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month SNSE price target is $50.00, with a high forecast of $50.00 and a low of $50.00. The median price target is shown in the chart above when available. This implies +284.6% potential upside from the current price of $13.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.